File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: Review: Using serum osteopontin to help identify pleural mesothelioma

TitleReview: Using serum osteopontin to help identify pleural mesothelioma
Authors
Issue Date2006
PublisherB M J Publishing Group. The Journal's web site is located at http://thorax.bmjjournals.com/
Citation
Thorax, 2006, v. 61 n. 1, p. 22 How to Cite?
AbstractSerum osteopontin levels were compared in 76 patients with surgically staged pleural mesothelioma, 69 with non‐malignant asbestos disease, and 45 non‐exposed controls. Tumour osteopontin was also assessed in the patients with mesothelioma. Comparing age matched subjects with and without exposure to asbestos (in the absence of malignant disease), the authors concluded that there were no significant differences in mean (SE) serum levels of osteopontin between the groups (30 (3) ng/ml and 20 (4) ng/ml, respectively; p=0.06). However, serum osteopontin levels were significantly higher in the group with pleural mesothelioma than in the asbestos exposed controls (133 (10) ng/ml v 30 (3) ng/ml, p<0.001). Thirty six of the 38 available samples of tumour tissue (94.7%) stained positive for osteopontin on immunohistochemistry. In the groups exposed to asbestos, Receiver‐Operating‐Characteristic (ROC) analysis of serum osteopontin levels noted a sensitivity of 77.6% and specificity of 85.5% (at a cut off of 48.3 ng/ml) for the diagnosis of mesothelioma; this improved to 84.6% and 88.4%, respectively, with a cut off value of 62.4 ng/ml for patients with confirmed stage I mesothelioma. This study shows that tissue immunohistochemistry and serum ELISA assay for osteopontin can be used to help distinguish individuals with pleural mesothelioma from those with non‐malignant pulmonary disease who have been exposed to asbestos.
Persistent Identifierhttp://hdl.handle.net/10722/195833
ISSN
2015 Impact Factor: 8.121
2015 SCImago Journal Rankings: 3.650

 

DC FieldValueLanguage
dc.contributor.authorHui, KMC-
dc.date.accessioned2014-03-13T08:50:39Z-
dc.date.available2014-03-13T08:50:39Z-
dc.date.issued2006-
dc.identifier.citationThorax, 2006, v. 61 n. 1, p. 22-
dc.identifier.issn0040-6376-
dc.identifier.urihttp://hdl.handle.net/10722/195833-
dc.description.abstractSerum osteopontin levels were compared in 76 patients with surgically staged pleural mesothelioma, 69 with non‐malignant asbestos disease, and 45 non‐exposed controls. Tumour osteopontin was also assessed in the patients with mesothelioma. Comparing age matched subjects with and without exposure to asbestos (in the absence of malignant disease), the authors concluded that there were no significant differences in mean (SE) serum levels of osteopontin between the groups (30 (3) ng/ml and 20 (4) ng/ml, respectively; p=0.06). However, serum osteopontin levels were significantly higher in the group with pleural mesothelioma than in the asbestos exposed controls (133 (10) ng/ml v 30 (3) ng/ml, p<0.001). Thirty six of the 38 available samples of tumour tissue (94.7%) stained positive for osteopontin on immunohistochemistry. In the groups exposed to asbestos, Receiver‐Operating‐Characteristic (ROC) analysis of serum osteopontin levels noted a sensitivity of 77.6% and specificity of 85.5% (at a cut off of 48.3 ng/ml) for the diagnosis of mesothelioma; this improved to 84.6% and 88.4%, respectively, with a cut off value of 62.4 ng/ml for patients with confirmed stage I mesothelioma. This study shows that tissue immunohistochemistry and serum ELISA assay for osteopontin can be used to help distinguish individuals with pleural mesothelioma from those with non‐malignant pulmonary disease who have been exposed to asbestos.-
dc.languageeng-
dc.publisherB M J Publishing Group. The Journal's web site is located at http://thorax.bmjjournals.com/-
dc.relation.ispartofThorax-
dc.rightsThorax. Copyright © B M J Publishing Group.-
dc.rightsThis article has been accepted for publication in Thorax, 2006, v. 61 n. 1, p. 22 following peer review and can also be viewed on the journal’s website at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2080695/-
dc.titleReview: Using serum osteopontin to help identify pleural mesotheliomaen_US
dc.typeArticleen_US
dc.identifier.emailHui, KMC: chris.hui@hku.hk-
dc.identifier.volume61-
dc.identifier.issue1-
dc.identifier.spage22-
dc.identifier.epage22-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats